Urologic Oncology: Seminars and Original Investigations
Volume 25, Issue 2 , Pages 101-109 , March 2007

Survival benefit for early hormone ablation in biochemically recurrent prostate cancer

  • Todd C. Tenenholz, M.D.

      Affiliations

    • Department of Radiation Oncology, Medical College of Virginia Hospitals, Virginia Commonwealth University, Richmond, VA 23298-0058, USA
    • ,
  • Christian Shields, M.A.

      Affiliations

    • Department of Radiation Oncology, Medical College of Virginia Hospitals, Virginia Commonwealth University, Richmond, VA 23298-0058, USA
    • ,
  • V. Ramakrishnan Ramesh, Ph.D.

      Affiliations

    • Department of Biostatistics, Medical College of Virginia Hospitals, Virginia Commonwealth University, Richmond, VA 23298, USA
    • ,
  • Oscar Tercilla, M.D.

      Affiliations

    • Department of Radiation Oncology, Medical College of Virginia Hospitals, Virginia Commonwealth University, Richmond, VA 23298-0058, USA
    • Department of Radiation Oncology, Hunter-Holmes McGuire Veterans Affairs Medical Center, Richmond, VA 23249, USA
    • ,
  • Michael P. Hagan, M.D.

      Affiliations

    • Department of Radiation Oncology, Medical College of Virginia Hospitals, Virginia Commonwealth University, Richmond, VA 23298-0058, USA
    • Department of Radiation Oncology, Hunter-Holmes McGuire Veterans Affairs Medical Center, Richmond, VA 23249, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-804-828-2795 or +1-804-628-1032; fax: +1-804-828-6042.

Received 14 November 2005 ,Revised 1 March 2006 ,Accepted 2 March 2006.

References 

  1. Huggins C, Hodges CV. Studies on prostate cancer: I (The effect of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate). Cancer Res. 1941;1:293–297
  2. Klotz L. Hormone therapy for patients with prostate carcinoma. Cancer. 2000;88:3009–3014
  3. Moul JW. Variables in predicting survival based on treating “PSA-only” relapse. Urol Oncol. 2003;21:292–304
  4. Johnstone PA, Booth R, Riffenburgh RH, et al. Initiation of salvage therapy for prostate cancer. Prostate Cancer Prostatic Dis. 2002;5:136–143
  5. Messing EM, Manola J, Sarosdy M, et al. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med. 1999;341:1781–1788
  6. The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council Trial. Br J Urol. 1997;79:235–246
  7. Scherr D, Swindle PW, Scardino PT. National Comprehensive Cancer Network guidelines for the management of prostate cancer. Urology. 2003;61:14–24
  8. Zagars GK, Pollack A. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol. 1997;44:213–221
  9. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591–1597
  10. McCarthy JF, Catalona WJ, Hudson MA. Effect of radiation therapy on detectable serum prostate specific antigen levels following radical prostatectomy: Early versus delayed treatment. J Urol. 1994;151:1575–1578
  11. Hanlon AL, Diratzouian H, Hanks GE. Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer. Int J Radiat Oncol Biol Phys. 2002;53:297–303
  12. Lee WR, Hanks GE, Hanlon A. Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: Clinical observations. J Clin Oncol. 1997;15:230–238
  13. Hanks GE, D’Amico A, Epstein BE, et al. Prostatic-specific antigen doubling times in patients with prostate cancer: A potentially useful reflection of tumor doubling time. Int J Radiat Oncol Biol Phys. 1993;27:125–127
  14. DeWeese TL, Song DY. Current evidence for the role of combined androgen suppression and radiation in the treatment of adenocarcinoma of the prostate. Urology. 2000;55:169–174
  15. Pollack A, Zagars GK. Androgen ablation in addition to radiation therapy for prostate cancer: Is there true benefit?. Semin Radiat Oncol. 1998;8:95–106
  16. Litwin MS. Quality of life following definitive therapy for localized prostate cancer: Potential impact of multiple therapies. Curr Opin Urol. 2003;13:153–156
  17. American Society for Therapeutic Radiation and Oncology (ASTRO). Consensus statement guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys. 1997;37:1035–1041
  18. Partin AW, Mangold LA, Lamm DM, et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology. 2001;58:843–848
  19. Pilepich MV, Caplan R, Byhardt RW, et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: Report of Radiation Therapy Oncology Group Protocol 85–31. J Clin Oncol. 1997;15:1013–1021
  20. Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med. 1997;337:295–300
  21. Granfors T, Modig H, Damber JE, et al. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: A prospective randomized study. J Urol. 1998;159:2030–2034
  22. Pollack A, Zagars GK, Kavadi VS. Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer. Cancer. 1994;74:670–678
  23. Sylvester J, Grimm P, Blasco J, et al. The role of androgen ablation in patients with biochemical or local failure after definitive radiation therapy: A survey of practice patterns of urologists and radiation oncologists in the United States. Urology. 2001;58:65–70
  24. Moul JW, Wu H, Sun L, et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol. 2004;171:1141–1147

☆ This work was supported by the Berlex Oncology Foundation for a clinical biostatistics training grant for T.C.T.

PII: S1078-1439(06)00060-3

doi: 10.1016/j.urolonc.2006.03.002

Urologic Oncology: Seminars and Original Investigations
Volume 25, Issue 2 , Pages 101-109 , March 2007

Article Tools

* Image Usage & Resolution